Related Experiment Videos
Dose-dependent haemodynamic response to prenalterol in patients with congestive heart failure
Insights
Prenalterol
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) presents complex hemodynamic challenges.
- Understanding drug effects on cardiac function is crucial for patient management.
Purpose of the Study:
- To evaluate the hemodynamic effects of prenalterol in patients with congestive heart failure.
- To assess the influence of prenalterol dosage and vasodilator pretreatment on cardiac performance.
Main Methods:
- Investigated three doses of prenalterol (12.5, 25, 50 micrograms) in 18 CHF patients.
- Compared outcomes with prenalterol alone versus prenalterol after hydralazine and isosorbide dinitrate.
- Monitored cardiac index (CI), pulmonary artery pressure (PAP), heart rate (HR), and stroke volume index (SVI).
Main Results:
- A dose-dependent increase in HR was observed in 7/12 patients, inversely correlated with catecholamine levels.
- Cardiac index (CI) and stroke volume index (SVI) showed inconsistent improvements.
- Vasodilator pretreatment did not enhance hemodynamic response; 4/17 patients experienced increased arrhythmias.
Conclusions:
- Prenalterol's hemodynamic effects in CHF are variable and not consistently improved by vasodilators.
- High resting catecholamine levels in severe CHF may blunt heart rate response to prenalterol.
- Potential arrhythmogenic properties warrant caution with prenalterol use in CHF patients.
Abstract:
The effect of three doses of prenalterol, 12.5, 25 and 50 micrograms, on cardiac index (CI), pulmonary artery pressure (PAP), heart rate (HR), and stroke volume index (SVI) was investigated in 18 patients with congestive heart failure (CHF). Twelve patients received only prenalterol, while 6 patients received prenalterol 1 hour after an oral dose of hydralazine and isosorbid dinitrate. In 7 out of 12 patients a dose-dependent increase in HR was observed. The response of HR was inversely correlated to resting catecholamine levels; patients with high resting catecholamines--these are patients with severe CHF--did not show any increase in HR. CI increased in 8 out of 12 patients (average 1 . 1/min m) and SVI in 5 out of 12 patients. This inconsistent response was not dependent on left ventricular ejection fraction or plasma catecholamines at rest. Pretreatment with vasodilators did not improve the haemodynamic response to prenalterol. Four out of 17 patients demonstrated an increase in severity of arrhythmias suggestive of arrhythmogenic properties of prenalterol.